CSL Behring has agreed to acquire Calimmune, a developer of gene therapy treatments that is backed by an unnamed pharmaceutical firm.

Legend Capital has celebrated an exit as Berry Genomics completed a reverse merger with Chengdu Tianxing Instrument and Meter in a deal worth $653m.

Boston Scientific, Medtronic and GlaxoSmithKline returned to support a $30m series D round for biomedical technology company SetPoint Medical.

Qianhai Xino-backed Akeso Biopharma will use the series B capital to build a drug manufacturing facility in China.

Shuanglu Pharma-backed CF PharmTech has raised $65m in a series D round led by fund managed by China state-owned State Development & Investment Corporation.

GV-backed Freenome has raised $7m in a series A extension led by Section 32, the venture capital firm launched by former GV chief executive Bill Maris.

Amgen Ventures and Alexandria Real Estate Equities have invested $6m in GNS Healthcare, which already counts Celgene, Cambia Health and Mitsui as investors.

Boston Scientific was among the investors that provided $14.1m in series C-1 funding for the medical device developer, taking its total funding to about $46m.